Jacobson Pharma
Jacobson Pharma Corporation Limited, commonly known as Jacobson Pharma, is a prominent player in the pharmaceutical industry, headquartered in Hong Kong (HK). Founded in 2015, the company has rapidly established itself as a leader in the development, manufacturing, and distribution of generic and proprietary pharmaceuticals across Asia and beyond. Specialising in a diverse range of therapeutic areas, Jacobson Pharma offers a unique portfolio of high-quality products, including prescription medications and over-the-counter solutions. The company is recognised for its commitment to innovation and quality, ensuring that its offerings meet stringent regulatory standards. With a strong market position, Jacobson Pharma has achieved significant milestones, including strategic partnerships and expansions that enhance its operational capabilities. As a trusted name in the pharmaceutical sector, Jacobson Pharma continues to focus on delivering effective healthcare solutions to improve patient outcomes.
DitchCarbon Score
How does Jacobson Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jacobson Pharma's score of 26 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jacobson Pharma's reported carbon emissions
In 2023, Jacobson Pharma reported total carbon emissions of approximately 63,219,040 kg CO2e, comprising 39,452,960 kg CO2e from Scope 1, 23,612,700 kg CO2e from Scope 2, and 153,380 kg CO2e from Scope 3 emissions. This marked an increase from 2022, where total emissions were about 60,328,700 kg CO2e, with Scope 1 emissions at 37,247,570 kg CO2e and Scope 2 at 23,114,050 kg CO2e. In 2021, the company recorded total emissions of approximately 53,283,000 kg CO2e, indicating a trend of rising emissions over the past few years. Jacobson Pharma has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction strategies suggests a need for enhanced focus on sustainability practices within the organisation. The company’s emissions intensity, calculated as GHG emissions per unit of revenue, was reported at 0.01349 for 2024, reflecting their operational impact relative to financial performance. Overall, while Jacobson Pharma has provided emissions data across multiple scopes, the lack of clear reduction targets highlights an opportunity for the company to strengthen its climate action commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 34,398,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 18,749,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 136,000 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Jacobson Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
